Webinar: ACR/CHEST ILD Guidelines in Practice| Video: All the Lonely People

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Caring for Pediatric Patients During a Pandemic: Q&A with Jay Mehta, MD

  |  

Caring for pediatric patients during a pandemicin the age of COVID-19 requires adaptations, says Jay Mehta, MD, Children’s Hospital of Philadelphia. “The one exposure that seems to put [pediatric] patients at risk is if they are on higher doses of steroids, with some data suggesting worse outcomes. We just put out guidelines telling providers to reduce steroids in their patients to the lowest dose that can adequately control their disease.”

In Memoriam … J. Timothy Harrington, MD, MACR: July 6, 1940–June 23, 2020

William Arnold, MD; Tim Bartholow, MD; Drew Johnson, MS, MBA; Joel Kremer, MD; Daniel Malone, MD; Eric D. Newman, MD; Kenneth Saag, MD; & Douglas White, MD  |  

June saw the passing of a beloved colleague, mentor and friend to many in the rheumatology community when J. Timothy Harrington, MD, died of pancreatic cancer in his hometown of Madison, Wis. Dr. Harrington trained at Massachusetts General Hospital, the National Institutes of Health National Cancer Institute and UT Southwestern Medical Center, and served on…

Research Beyond COVID-19: Collateral Damage

Nancy A. Delnay, MSN, CNP; Charmayne M. Dunlop-Thomas, MS, MPH; Rebecca J. Cleveland, PhD; Cynthia S. Crowson, PhD; Joshua Stefanik, MSPT, PhD; Jungwha Lee, PhD, MPH; Kendra Young, MSPH, PhD; & Dina L. Jones, PT, PhD  |  

COVID-19 has generated an outpouring of fast-paced, late-breaking new developments. The majority of countries (188) around the world have reported cases of COVID-19.1 As of April 1, 2020, the Centers for Disease Control and Prevention had reported cases in every U.S. jurisdiction (50 states, District of Columbia, Puerto Rico, Guam, the Northern Mariana Islands and…

Zoledronate After Denosumab Does Not Fully Prevent Bone Loss

Marilynn Larkin  |  

NEW YORK (Reuters Health)—In postmenopausal women and men treated for at least two years with denosumab, a single infusion of zoledronate given after denosumab discontinuation does not completely prevent bone turnover and loss, researchers say. Given the findings, “bone mineral density (BMD) should probably be higher than the current target for discontinuation of bisphosphonate treatment…

Tocilizumab Fails to Help COVID-19 Patients in Italian Study

Emilio Parodi & Carl O'Donnell  |  

(Reuters)—Roche’s rheumatoid arthritis drug Actemra (tocilizumab) failed to help patients with early-stage COVID-19 pneumonia in an Italian study, the latest instance in which an anti-inflammatory drug has fallen through in a coronavirus trial. Despite the setback, the Swiss drugmaker said that it is pressing ahead with testing tocilizumab in another trial against COVID-19, the disease…